Phosphate ester compound as well as composition, preparation method and application thereof

Lipid nanoparticles prepared by reacting novel phosphate compounds with ethanolamine solve the problem of insufficient stability of existing liposomes, improve the transfection rate and stability, and are suitable for the field of nucleic acid vaccines, especially in transportation conditions Harsh areas.

CN118994230AActive Publication Date: 2024-11-22SHANGHAI MODERN PHARMACEUTICAL ENGINEERING RESEARCH CENTER CO LTD +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202310560431.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-17
Publication Date
2024-11-22
Estimated Expiration
2043-05-17

AI Technical Summary

Technical Problem

The insufficient stability of existing liposomes limits the application and development of nucleic acid drugs, especially in areas with harsh transportation conditions and insufficient refrigeration, which affects the effectiveness and transfection rate of the drugs.

Method used

Provided is a novel phosphate compound whose structure includes C7-C10 alkyl and C1-C6 alkenyl or -(CH2)rOH group, prepared by reacting with ethanolamine to form stable lipid nanoparticles, enhancing the support. Transfection rate and stability of siRNA lipid nanoparticles.

Benefits of technology

Improve the stability and transfection rate of lipid nanoparticles, can be stored at room temperature for more than 30 days, with an average particle size of 80-100nm, an encapsulation rate of up to 93%, and a cell viability of 96-98%. It is suitable for use in Nucleic acid vaccine field.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994230A_ABST
    Figure CN118994230A_ABST
Patent Text Reader

Abstract

The invention discloses a phosphate ester compound as well as a composition, a preparation method and application thereof. The invention provides a phosphate ester compound as shown in a formula I in the specification. The compound is novel in structure, and the stability is greatly improved. The compound provided by the invention can be used for preparing lipid nanoparticles, has higher transfection rate on siRNA-loaded lipid nanoparticles, and is more suitable for being applied to the field of nucleic acid vaccines. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a phosphate compound, a composition, a preparation method and an application thereof. Background Art

[0002] At present, the application and development of gene therapy and nucleic acid drugs are limited by their large molecular weight, poor stability, low transfection rate, and difficulty in escaping cells. However, with the continuous development of carrier technology, cationic lipids have evolved from permanent cationic lipids with high cytotoxicity at the beginning to ionizable cationic lipids through continuous modification and improvement. The emergence and optimization of lipid nanoparticle (LNP) delivery systems have gradually solved the dilemma faced by this type of drug and maximized its efficacy.

[0003] Among the components of LNP, the key core component cationic lipid structure, which accounts for 50%, is the most important. Different cationic lipids not only affect the encapsulation effect of nucleic acid drugs, but also affect the stability of the formulation, the method of administration, the target of administration, the cell transfection rate, etc. An ideal cationic lipid needs to meet three characteristics: ① The ionizable hydrophilic amine head fully realizes mRNA enrichment. ② The hydrophobic hydrocarbon chain tail promotes self-assembly and fusion with phospholipid membranes. ③ The 1inkers connecting the head group and the tail hydrocarbon chain are biodegradable, so that the mRNA can be safely cleared by the body after delivery.

[0004] The successful use of the COVID-19 vaccine produced by Modema also showed us a new cationic lipid SM-102, which is used in intramuscular injection. However, the storage conditions of the commercially available SM-102 are harsh and it is not suitable for use in many underdeveloped areas with poor transportation conditions and refrigeration. Summary of the invention

[0005] In order to overcome the problem of insufficient stability of liposomes in the prior art, the present invention provides a phosphate compound, a composition, a preparation method and an application thereof. The phosphate compound of the present invention as shown in Formula I has a novel structure and greatly improved stability; it has a higher transfection rate for siRNA-carrying lipid nanoparticles and is more suitable for application in the field of nucleic acid vaccines.

[0006] The present invention solves the above technical problems through the following technical solutions.

[0007] The present invention provides a phosphate compound as shown in Formula I,

[0008]

[0009] Wherein R1 and R2 are independently C7-C 10 The alkyl group;

[0010] m is 0, 1, 2 or 3; n is 1, 2, 3, 4, 5 or 6; and m+n≤7.

[0011] The present invention provides a phosphate compound as shown in Formula Ia,

[0012]

[0013] Wherein R1 and R2 are independently C7-C 10 The alkyl group;

[0014] m is 0, 1, 2 or 3; n is 1, 2, 3, 4, 5 or 6; and m+n≤7;

[0015] R4 is C1-C6 alkyl, C2-C6 alkenyl or -(CH2) r OH;

[0016] r is 1, 2, 3, 4, 5 or 6.

[0017] In a certain embodiment, in the phosphate compound as shown in Formula I or Formula Ia, certain groups have the following definitions, and the definitions of the unmentioned groups are as described in any embodiment of the present invention (this paragraph is hereinafter referred to as "in a certain embodiment").

[0018] In a certain embodiment, R1 and R2 may independently be n-heptyl, n-octyl, n-nonyl or n-decyl, for example, n-octyl.

[0019] In a certain embodiment, m is preferably 1.

[0020] In a certain embodiment, n is preferably 2.

[0021] In one embodiment, the phosphate compound as shown in Formula I may be a compound as shown in Formula I' below:

[0022]

[0023] Wherein, the definitions of R1 and R2 are as described in any one of the present invention.

[0024] In one embodiment, the phosphate compound as shown in Formula I can be the following compound,

[0025]

[0026] In one embodiment, the phosphate compound as shown in Formula Ia further comprises an anion, which may be a chloride ion, a bromide ion, an iodide ion, a fluoride ion, an acetate ion, a formate ion, a trifluoroacetate ion, a difluoroacetate ion, a trichloroacetate ion or a phosphate ion, such as an acetate ion.

[0027] In a certain embodiment, R4 is preferably a C1-C4 alkyl group, more preferably a methyl group, an ethyl group, an n-propyl group or an n-butyl group, and further preferably a methyl group.

[0028] In one embodiment, the phosphate compound as shown in Formula Ia may be a compound as shown in Formula Ia' below:

[0029]

[0030] Wherein, R1, R2 and R4 are defined as described in any one of the present invention.

[0031] The present invention also provides a method for preparing a phosphate compound as shown in formula I, which comprises the following steps A: reacting a compound as shown in formula II with ethanolamine to obtain the compound as shown in formula I,

[0032]

[0033] Wherein, R1, R2, m and n are defined as described in any one of the present invention.

[0034] In the method for preparing the phosphate compound represented by Formula I, the reaction conditions and operations may be the common conditions and operations for such reactions in the art, and the present invention particularly prefers the following conditions:

[0035] Preferably, the reaction temperature in step A may be 65°C-70°C, for example 70°C;

[0036] and / or, the molar ratio of the compound represented by formula II to the ethanolamine is preferably 1:20;

[0037] And / or, the reaction in step A may be carried out in a solvent, and the solvent is preferably an alcohol solvent, such as ethanol;

[0038] And / or, the preparation method of the phosphate compound represented by Formula I may further include a post-treatment step, which is a conventional post-treatment step of an organic reaction in the art, and may include one or more of dilution, extraction, drying, concentration, and purification.

[0039] The preparation method of the compound of formula I may further include a preparation method of the compound of formula II, which includes the following step B: in a solvent, in the presence of an iodine reagent, 2-bromoethanol, the compound of formula III and the compound of formula IV react to obtain the compound of formula II.

[0040]

[0041] Preferably, the reaction temperature in step B may be -5°C to 3°C, for example 0°C;

[0042] And / or, the solvent in step B is preferably a halogenated hydrocarbon solvent and / or a heteroaromatic ring reagent, more preferably a halogenated hydrocarbon solvent and a heteroaromatic ring reagent, such as dichloromethane and pyridine;

[0043] And / or, the iodine reagent is preferably elemental iodine;

[0044] And / or, the molar ratio of the compound represented by formula III to the compound represented by formula IV is preferably 1:1.6;

[0045] And / or, the molar ratio of the compound represented by formula III to the 2-bromoethanol is preferably 1:1.6.

[0046] The present invention also provides a compound as shown in formula II,

[0047]

[0048] Wherein, R1, R2, m and n are as defined in any one of the present invention;

[0049] Preferably, the compound represented by formula II is the following compound,

[0050]

[0051] The present invention also provides a lipid nanoparticle, which comprises a substance A, wherein the substance A is a phosphate compound represented by formula I or a phosphate compound represented by formula Ia as described above.

[0052] In one embodiment, the lipid nanoparticle further comprises a diluent, which may be a pH buffer, such as a pH 4 buffer.

[0053] In one embodiment, the lipid nanoparticles further include phospholipids.

[0054] In a certain embodiment, the phospholipid is a conventional phospholipid in the art, preferably distearoylphosphatidylcholine (DSPC), dimyristoylphosphocholine (DMPC), dioleoylphosphocholine (DOPC), palmitoylphosphocholine (DPPC), heneicosanoylphosphocholine (DUPC) or palmitoylphosphocholine (POPC), such as DSPC.

[0055] In a certain embodiment, the lipid nanoparticles further include a sterol, which can be selected from one or more of cholesterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, ursolic acid and d-tocopherol, such as cholesterol.

[0056] In a certain embodiment, the lipid nanoparticles also include PEG lipids, and the PEG lipids can be selected from one or more of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol and PEG-modified dialkylglycerol, such as 1-methoxypolyethylene glycol 2000-2,3-dimyristoylglycerol (PEG2000-C-DMG).

[0057] In one embodiment, the molar ratio of the substance A to the phospholipid may be 50:8.0 to 50:12.0, for example, 50:10.

[0058] In a certain embodiment, the molar ratio of the substance A to the sterol may be 50:37.0 to 50:39.0, for example, 50:38.5.

[0059] In one embodiment, the molar ratio of the substance A to the PEG lipid may be 50:1.0 to 50:2.0, for example, 50:1.4.

[0060] In a certain embodiment, the lipid nanoparticles are composed of the substance A, the diluent, the phospholipid, the PEG lipid and the sterol.

[0061] In one embodiment, the lipid nanoparticle further comprises a therapeutic agent and / or a prophylactic agent.

[0062] In a certain embodiment, the therapeutic agent and / or preventive agent may be one or two or more nucleic acids, preferably messenger RNA (mRNA) or small interfering RNA (siRNA), such as siRNA.

[0063] In a certain embodiment, the average particle size of the lipid nanoparticles is preferably 80 to 100 nm.

[0064] In a certain embodiment, the pKa of the lipid nanoparticles is preferably 6.2-6.8.

[0065] In a certain embodiment, the cell viability of the lipid nanoparticles is preferably 96% to 98%.

[0066] The lipid nanoparticles can be prepared by conventional methods in the art, preferably by using microfluidic mixing technology.

[0067] The present invention also provides a pharmaceutical composition comprising the lipid nanoparticles as described above and a pharmaceutically acceptable carrier.

[0068] The present invention also provides a use of a substance A as a formulation excipient, wherein the substance A is a phosphate compound represented by formula I or a phosphate compound represented by formula Ia as described above; preferably, the formulation excipient is a cationic lipid.

[0069] Unless otherwise specified, the terms used in the present invention have the following meanings:

[0070] Certain chemical groups defined herein are preceded by a simplified symbol to indicate the total number of carbon atoms present in the group. For example, C7-C 10 Alkyl or C 7-10 Alkyl refers to an alkyl group as defined below having a total of 7, 8, 9 or 10 carbon atoms. The total number of carbon atoms in the shorthand notation does not include carbons that may be present in substituents of the group being described.

[0071] The term "comprising" is an open expression, that is, including the contents specified in the present invention but not excluding other contents.

[0072] The term "alkyl" refers to a group having a specified number of carbon atoms (e.g., C7 to C 10 ), linear, branched, saturated, monovalent hydrocarbon groups. Alkyl groups include, but are not limited to, n-heptyl, n-octyl, n-nonyl, or n-decyl.

[0073] The term "alkenyl" refers to a linear or branched, unsaturated, monovalent hydrocarbon radical having a specified number of carbon atoms (e.g., C2-C6) and having one or more (e.g., 1, 2, or 3) carbon-carbon sp 2 Double bond. Alkenyl groups include but are not limited to: vinyl, wait

[0074] The term "pharmaceutically acceptable carrier" refers to excipients and additives used in the production of drugs and the preparation of prescriptions. It is all substances contained in drug preparations except the active ingredients. For details, please refer to the Pharmacopoeia of the People's Republic of China (2020 edition) or Handbook of Pharmaceutical Excipients (Raymond C Rowe, 2009).

[0075] The term "treat" refers to any of the following: (1) alleviating one or more biological manifestations of a disease; (2) interfering with one or more points in the biological cascade that initiates a disease; or (3) slowing the progression of one or more biological manifestations of a disease.

[0076] The term "prevention" refers to reducing the risk of disease. Without violating the common sense in the art, the above-mentioned preferred conditions can be combined arbitrarily to obtain the preferred embodiments of the present invention.

[0077] The term "therapeutically effective amount" refers to an amount of a compound that is sufficient to effectively treat a disease or condition described herein when administered to a patient."Therapeutically effective amount" will vary depending on the compound, the condition and its severity, and the age of the patient to be treated, but can be adjusted as needed by those skilled in the art.

[0078] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0079] Room temperature in the present invention refers to 10-30°C.

[0080] The reagents and raw materials used in the present invention are commercially available.

[0081] The positive progress of the present invention is that the compound provided by the present invention has a novel structure and can be used to prepare lipid nanoparticles. The compound of the present invention has a unique hydrophobic end of a phosphate group containing a C1-C4 alkyl group and a trialkyl ester chain, and the stability is greatly improved, and it can be stored for more than 30 days at room temperature. The lipid nanoparticles containing the phosphate compound of the present invention have an average particle size that is stably distributed in 80 to 100 nm, an encapsulation rate of more than 93%, a PDI of less than 0.061, an absolute value of the Zeta potential of more than 0.17 mv, a pKa value of 6.2 to 6.8, and a cell viability of 96% to 98%. After the siRNA-carrying lipid nanoparticles enter the cell through endocytosis, under the acidic conditions of the lysosome, the compound of the present invention can make the entire nano preparation escape into the cytoplasm through the proton sponge effect, and the transfection rate can reach 58% to 62%. The siRNA-carrying lipid nanoparticles are more suitable for application in the field of nucleic acid vaccines. DETAILED DESCRIPTION

[0082] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0083] Example 1 The following procedure can be used to synthesize the phosphate compounds shown in Formula I

[0084] Unless otherwise noted, all solvents and reagents used were commercially available and used as received. 1 H-NMR spectra were recorded in CDCl3 at 300 K using a Bruker Ul trashield 400 MHz instrument. Chemical shifts are relative to 1 H is reported as parts per million (ppm) relative to TMS (0.00). Silica gel chromatography was performed on a TELEDYNE ISCO Rf 200 instrument, using SEPAFLASH fast column (particle size: 40-63 microns). All final compounds were passed through a Thermo Ultimate 3000 (CAD) instrument with reverse phase UHPLC (retention time, RT, in minutes), UHPLC XB-C18 high efficiency column (2.1mm, 100mm, 1.8μm), at a flow rate of 0.5mL / min, mobile phase A: water containing 0.1% trifluoroacetic acid (TFA), mobile phase B: methanol containing 0.1% TFA, gradient elution: in 40 minutes, from 90% mobile phase A / 10% mobile phase B to 10% mobile phase A / 90% mobile phase B, determined to be more than 90% pure. The injection volume was 5μL, and the column temperature was 60°C. Detection was performed in positive ion mode based on electrospray ionization (ESI) using a Waters SQD mass spectrometer (Mi lford, MA, USA) and an evaporative light scattering detector.

[0085] Representative procedures

[0086]

[0087] Preparation of 9-heptadecanol (Scheme A):

[0088]

[0089] Chemical formula: C 17 H 36 O

[0090] Molecular weight: 256.47

[0091]

[0092] A magnesium bar (4.25 g, 177 mmol) was added to a reaction flask, 500 ml of anhydrous tetrahydrofuran (THF) was added as a solvent, bromooctane (37.99 g, 196 mmol) and 4 iodine grains (1.33 g, 5.24 mmol) were added dropwise, and the reaction was heated to 68°C until most of the magnesium bar was dissolved, and nonanal (25.51 g, 179 mmol) was slowly added dropwise. After the addition was complete, the reaction was continued at 68°C for 3.5 hours. The reaction was completed by TLC hexane: ethyl acetate = 5: 1 phosphomolybdic acid colorimetric detection. Water was added to quench, the pH was adjusted to slightly acidic with dilute hydrochloric acid, and extracted with ethyl acetate. After drying over anhydrous sodium sulfate, the organic layer was filtered and rotary evaporated in a vacuum. The crude product was purified by silica gel chromatography (0-5% ethyl acetate / n-hexane) to obtain 9-heptadecanol (24.13 g, 94 mmol, yield: 53%, purity: 97.32%). For C 17 H 36 O, MS (ES): m / z (MH +)257.47. 1 H NMR (600MHz, DMSO-d6) δ4.26 (d, J=5.4Hz, 1H), 1.44-1.28 (m, 28H), 0.93 (t, J=7.0Hz, 6H).

[0093] Preparation of 2-bromoethylethylheptadecan-9-yl phosphate (Scheme B):

[0094]

[0095] Chemical formula: C 21 H 44 O4B

[0096] Molecular weight: 471.46

[0097]

[0098] Add 2-bromoethanol (8.03 g, 64.78 mmol) dried over molecular sieves to 27.44 g pyridine and 350 ml anhydrous dichloromethane (CH2Cl2) dried over potassium hydroxide (KOH), stir in a 0°C refrigerator, add a solution of diethylphosphite chloride (10.00 g, 64.09 mmol) in CH2Cl2 (20 ml) dropwise at 0°C, and stir for 10 minutes. Add a stoichiometric amount of iodine particles (8.23 g, 32.42 mmol), which gradually dissolve in the reaction solution, gradually becoming yellow-brown turbid. Add a small amount of diethylphosphite chloride (0.50 g, 3.2 mmol) to titrate, and the reaction solution becomes colorless and transparent, and a large amount of white salt is precipitated to form a large amount of precipitation. Filter, take the filtrate, shake for 3 minutes, and then filter again. When no white solid is precipitated, reset the last filtered filtrate to stir under ice bath conditions. 9-Heptadecanol (10.45 g, 40.74 mmol) dissolved in 20 ml CH2Cl2 and 2.80 g pyridine was added dropwise. The reaction was completed after about 2 hours. The reaction was completed by TCL silica gel plate: hexane-acetone, 8:2 phosphomolybdic acid colorimetric detection. The reaction mixture was diluted with an equal volume of CH2Cl2. It was washed twice with 10% KHSO4, 10% potassium phosphate buffer (pH = 7), dried with Na2SO4, and vacuum rotary evaporated to obtain 21.03 g of yellow liquid crude product, which was purified by silica gel chromatography (0-30% ethyl acetate / n-hexane) to obtain 2-bromoethylethyl heptadecan-9-yl phosphate (15.03 g, 31.88 mmol, yield: 78.25%). For C 21 H 44 O4BrP, MS (ES): m / z (MH + )472.46.

[0099] 1H NMR (600MHz, CDCl3) δ4.31 (qt, J=12.6, 6.2Hz, 1H), 4.21 (d, J=7.9Hz, 2H), 4.10-3.96 (m , 2H), 3.52-3.36 (m, 2H), 1.65-1.46 (m, 4H), 1.32-1.13 (m, 27H), 0.81 (t, J=7.0Hz, 6H).

[0100] Preparation of ethyl heptadecan-9-yl (2-((2-hydroxyethyl)amino)ethyl) phosphate (Scheme C)

[0101]

[0102] Chemical formula: C 23 H 50 NO5P

[0103] Molecular weight: 451.32

[0104]

[0105] 2-Bromoethylethyl heptadecan-9-yl phosphate (3.20 g, 6.80 mmol) was reacted with 20 times the amount of ethanolamine (8.32 g, 136.17 mmol) in an ethanol solvent (reaction concentration 0.5 M), the reaction temperature was 70°C, the reaction was carried out for 48 hours, after the reaction was completed, the reaction was detected by TCL silica gel plate: ethyl acetate-methanol, 7:1 phosphomolybdic acid colorimetric detection, the reaction was completed, cooled to room temperature, an equal amount of water was added, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and rotary evaporated in a vacuum. Purified by silica gel chromatography (0-30% ethyl acetate / methanol), ethyl heptadecan-9-yl (2-((2-hydroxyethyl)amino)ethyl) phosphate (2.23 g, 4.92 mmol, yield: 72.49%, purity: 91.32%) was obtained. UPLC / ELSD: RT = 23.53 min, detection conditions: evaporative light scattering detector (ELSD), mobile phase A: water containing 0.1% trifluoroacetic acid (TFA), mobile phase B: methanol containing 0.1% TFA, gradient elution: from 90% mobile phase A / 10% mobile phase B to 10% mobile phase A / 90% mobile phase B in 40 minutes. For C 23 H 50 NO5P, MS (ES): m / z (MH + )452.35.

[0106] 1H NMR (600MHz, CDCl3) δ4.39-4.23 (m, 1H), 4.15-3.96 (m, 4H), 3.66-3.49 (m, 2H), 2.92-2.86 (m, 2H), 2.81-2.69 (m, 2H), 1.65-1.41 (m, 4H), 1.33-1.13 (m, 27H), 0.81 (t, J=7.0Hz, 6H).

[0107] Example 2: Blank lipid nanoparticles were prepared using microfluidic mixing technology. The specific preparation method is as follows:

[0108] Organic phase-lipid phase configuration: Weigh 124.11mg0.275mmol ethyl heptadecan-9-yl (2-((2-hydroxyethyl)amino)ethyl) phosphate (Compound 1) and 19.95mg0.0076mmol PEG2000-C-DMG, dissolve with a small amount of ethanol, add 40.37mg0.055mmol DSPC, add ethanol to dissolve by ultrasonic, and finally add 81.87mg0.212mmol cholesterol to dissolve by ultrasonic, and then dilute to 10mL with ethanol. Preparation of aqueous phase-pH 4 buffer: Preparation of 2mol / L glacial acetic acid, dilute 6mL glacial acetic acid to 50mL, and obtain 2mol / L glacial acetic acid. Take 20.5ml of 2mol / L glacial acetic acid solution, 1.22g of sodium acetate, dilute to 1L with water, and shake well to obtain aqueous phase-pH 4 buffer.

[0109] 1) Aspirate the two-phase solution into the syringe respectively, then connect the syringe outlet and the sample introduction tube and fix them on the syringe pump.

[0110] 2) Click Run, observe the outflow tube flow rate stabilize (usually discard the first 200 microliters of liquid), and collect the outflowing liquid with the collection tube. Generally stop collecting 1-2 seconds before the end of the injection, and discard the last 1-2 seconds of outflowing liquid.

[0111] 3) Set the flow rate: the organic phase flow rate is set to 1 mL / min, the aqueous phase flow rate is set to 3 mL / min, and the total flow rate is 4 mL / min.

[0112] 4) After the experiment, rinse with water and ethanol at a low speed, then rinse with pure water at a low speed, and let in air to keep the chip clean. The blank lipid nanoparticles are prepared. After preparation, put them into a 100KD dialysis bag and dialyze them in 1000ml PBS with pH=7.4. Change the dialysis solution once and leave overnight to obtain a compound 1-LNP with a concentration of about 10mmol / L.

[0113] Example 3: Characterization of Blank Lipid Nanoparticles

[0114] Dynamic light scattering and Zeta potential analyzer were used to measure the particle size distribution of blank lipid nanoparticles.

[0115] The average particle size of compound 1-LNP is 95.63 nm, the PDI (polymer dispersibility index) is 0.061, the Zeta potential is -0.17 mv, and the EE% (encapsulation efficiency) is 93.42%.

[0116] Example 4: The pKa value of blank lipid nanoparticles was measured by TNS method. The specific preparation method is as follows:

[0117] Prepare buffer solution: weigh 7.66 g of sodium chloride, 0.77 g of ammonium acetate, 2.383 g of 4-hydroxyethylpiperazineethanesulfonic acid (Hepes), and 2.13 g of 2-(N-morpholino)ethanesulfonic acid (MES) and dissolve them in 1 L of purified water. Titrate with 0.1 M HCl and 0.1 M NaOH in steps of 0.5 to a pH value from 3 to 10. Take 3 mL for each pH value and place it in a PE tube.

[0118] Take 40 μL of 10 mmol / L LNP prepared in Example 2 and add it to the buffer of different pH values ​​prepared by the above method. Weigh 3.5 mg of 2-nitroaniline-4,4,5,5-tetracarboxylic acid (TNS) and dissolve it in 25 mL of dimethyl sulfoxide (DMSO) at a concentration of about 400 μmol. Mix 100 μL of TNS solution with 3 mL of blank nanoparticles prepared in Example 2, with excitation and emission wavelengths of 391 nm and 436 nm, respectively, and the fluorescence data is analyzed by s-type best fit. The pKa value is defined as the pH value that produces half-maximum fluorescence intensity. The pKa value of compound 1-LNP was measured to be 6.3.

[0119] Example 5: CCK-8 method was used to evaluate the safety of blank lipid nanoparticles for NIH-3T3 cell cytotoxicity. The specific preparation method is as follows:

[0120] 1) Prepare cell suspension and count 5×10 3 Inoculate the cell suspension in a 96-well plate, about 100 μL per well, in triplicate. Place the culture plate in an incubator for pre-culture for a period of time (37°C, 5% CO2).

[0121] 2) Add 10, 25, 50 μmol / L of the compound 1-LNP prepared in Example 2 to each well of the culture plate.

[0122] 3) The culture plate was placed in an incubator and incubated for 12 h. A culture medium containing 10% CCK-8 (Dojindo) (Thermo Fisher Scientific, CytoTox Non-Radioactive Cytotoxicity Assay: DMEM, RPMI).

[0123] 4) Place the culture plate in an incubator and incubate in the dark for 4 h, and measure the absorbance (OD) at 450 nm using an enzyme reader.

[0124] Viability calculation: Cell viability (%) = [A (drug addition) - A (blank)] / [A (0 drug addition) - A (blank)] × 100

[0125] A (drug added): OD value of the wells with cells, CCK-8 solution and drug solution

[0126] A (0 drug addition): OD value of the well with cells, CCK-8 solution but no drug solution

[0127] A (blank): OD value of the well without cells

[0128] The cell viability of compound 1-LNP was measured at 96.32%.

[0129] Example 6: Transfection efficiency of siRNA-loaded LNPs in NIH-3T3 cells

[0130] Preparation before the experiment: ① One day before transfection, seed 2×10 5 NIH-3T3 cells were placed in each well with 2 mL of culture medium (Thermo Fisher Scientific, CytoTox Non-Radioactive Cytotoxicity Assay: DMEM, RPMI). ② Prepare serum-free growth medium (Thermo Fisher Scientific, RealTime-Glo TM MT Cell Viability Assay: DMEM / F 12) and serum-containing medium (Thermo Fisher Scientific, RealTime-Glo TM MT Cell Viability Assay: DMEM / F12+10% FBS). ③ Prepare the required smartpool siRNA (Thermo Fisher (Invitrogen)) (5000 nM concentration), blank LNP prepared in Example 2, 96-well plates and other reagents and consumables.

[0131] Note: During these steps, the operator needs to follow strict aseptic operation procedures to avoid contamination from external pathogenic microorganisms. At all times, care should be taken to avoid the generation of bubbles or mechanical damage, as they will interfere with the cell throwing rate. It is also necessary to ensure that each sample can be clearly labeled to avoid misoperation or erroneous results.

[0132] Specific operations:

[0133] Step 1. One day before transfection, seed each well with 2 × 10 5 NIH-3T3 cells, use 2mL of culture medium, a total of 6 wells. Each well is covered with a centrifuge tube or plate sealing film and placed at 37°C. Step 2. On the day of transfection, add 20μL 5000nM smartpool siRNA (final concentration 50nM smartpool siRNA) to the serum-free growth medium and mix gently to evenly disperse. Step 3. Add 5μL of blank LNP mixture prepared with compound 1 to another serum-free growth medium and mix gently, taking care not to produce bubbles or particles. Step 4. Mix the liquids treated in steps 2 and 3 evenly and let stand for 5 minutes until the complex LNP / siRNA is formed. Step 5. Take out the 6-well plate and remove the growth medium (PBS can be used for elution); add 1.5mL of fresh serum-free medium, and the 6-well plate can be slightly moved to ensure even distribution. Step 6. Add the LNP / siRNA complex prepared in step 4 to a 6-well plate containing NIH-3T3 cells, 2 ml per well. Be careful to shake gently to allow the complex to spray the entire cell surface. Step 7. Fix the 6-well plate in a carbon dioxide incubator at 37°C for transfection. Incubate the cells for 6 hours, then replace the medium containing serum and culture the cells for 36 hours until the experiment is completed. 8. Use QPCR to detect changes in the expression of the target gene to evaluate the delivery effect and therapeutic effect of the LNP / siRNA complex.

[0134] The transfection rate of compound 1-LNP was measured to be 58.32%.

[0135] Example 7: Comparative stability test of compound 1 and SM-102

[0136] Compound 1: Ethyl heptadecan-9-yl (2-((2-hydroxyethyl)amino)ethyl) phosphate

[0137] Reference substance: Modema's SM-102cas number: 208925-47-6

[0138]

[0139] Analytical method: Compound 1 and reference substance were dissolved in appropriate amount of ethanol to obtain 1 mg / mL solution. Placed in a 25°C thermostat, purity was determined by UPLC / ELSD under the aforementioned detection conditions after 30 days, and the results were recorded. The retention time and purity of each sample solution at a specific period were listed in turn, and the stability of each sample was evaluated based on the test results.

[0140] Table 1 Stability test data

[0141]

[0142] From the above results, it can be seen that after being stored at room temperature for 30 days, the purity of compound 1 did not decrease significantly compared with the initial purity, while the purity of SM-102 decreased by about 3%. It can be seen that the stability of compound 1 is significantly improved compared with SM-102.

[0143] Example 8: Comparative test of compound 1-LNP and SM-102-LNP inducing mouse Luc expression

[0144] We selected mice as experimental subjects and administered various LNPs intravenously to mice (n=6) at a dose of 0.5 mg / kg (mpk) and measured bioluminescence at 3, 6, and 24 hours. In some cases, controls (e.g., PBS controls) were evaluated for comparison.

[0145] As shown in Table 2 below, at 3 hours, compound 1-LNP has the highest total flux, and the total flux of compound 1-LNP is higher than that of SM-102-LNP. In addition, at 6 hours and 24 hours, the overall flux of compound 1-LNP is also higher. In general, the flux of compound 1-LNP shows high stability before the flux gradually decreases to less than 10% of the initial flux over time.

[0146] Therefore, based on the results, we can conclude that the phosphate compounds shown in Formula I are very likely to be used in transfection applications, and these compounds can provide higher transfection efficiency in a short time relative to the SM-102 formulation. It should be noted that we used controls (e.g., PBS) during the evaluation process in order to compare and confirm the validity of the data.

[0147] Table 2 Experimental data of mouse expression of Luc

[0148]

Claims

1. A phosphate compound as shown in formula I, in, R1 and R2 are independently C7-C 10 The alkyl group; m is 0, 1, 2 or 3; n is 1, 2, 3, 4, 5 or 6; and m+n≤7.

2. The phosphate compound as shown in formula I according to claim 1, characterized in that: The phosphate compound as shown in Formula I satisfies one or more of the following conditions: (1) R1 and R2 are independently n-heptyl, n-octyl, n-nonyl or n-decyl, for example n-octyl; (2) m is 1; and (3) said n is 2.

3. The phosphate compound as shown in formula I according to claim 1 or 2, characterized in that: The phosphate compound as shown in formula I is a compound as shown in formula I' below: Wherein, R1 and R2 are defined as in claim 1 or 2.

4. The phosphate compound as shown in formula I according to claim 1, characterized in that: The phosphate compound as shown in Formula I is the following compound, 5. A phosphate compound as shown in formula Ia, in, R1 and R2 are independently C7-C 1o The alkyl group; m is 0, 1, 2 or 3; n is 1, 2, 3, 4, 5 or 6; and m+n≤7; R4 is C1-C6 alkyl, C2-C6 alkenyl or -(CH2) r OH; r is 1, 2, 3, 4, 5 or 6.

6. The phosphate compound as shown in formula Ia according to claim 5, characterized in that The phosphate compound as shown in Formula Ia satisfies one or more of the following conditions: (1) R1 and R2 are independently n-heptyl, n-octyl, n-nonyl or n-decyl, for example n-octyl; (2) m is 1; (3) n is 2; (4) The phosphate compound represented by Formula Ia comprises an anion, and the anion is chloride, bromide, iodide, fluoride, acetate, formate, trifluoroacetate, difluoroacetate, trichloroacetate or phosphate, such as acetate; and (5) R4 is a C1-C4 alkyl group, preferably a methyl group, an ethyl group, a n-propyl group or a n-butyl group, more preferably a methyl group.

7. The phosphate compound as shown in formula Ia according to claim 5, characterized in that The phosphate compound represented by Formula Ia is a compound represented by Formula Ia' below: Wherein, R1, R2 and R4 are defined as described in claim 5 or 6.

8. A method for preparing a phosphate compound as shown in formula I, comprising the following steps A: reacting a compound as shown in formula II with ethanolamine to obtain the compound as shown in formula I, in, R1, R2, m and n are as defined in any one of claims 1 to 4; Preferably, the method for preparing the phosphate compound as shown in Formula I satisfies one or more of the following conditions: (1) The reaction temperature in step A is 65°C-70°C, for example 70°C; (2) The molar ratio of the compound represented by formula II to the ethanolamine is 1:20; (3) The reaction in step A is carried out in a solvent, and the solvent is preferably an alcohol solvent, such as ethanol; and (4) the method for preparing the phosphate compound represented by formula I further comprises a post-treatment step, wherein the post-treatment step comprises one or more of dilution, extraction, drying, concentration and purification.

9. The method for preparing the phosphate compound as shown in Formula I as claimed in claim 8, characterized in that: The preparation method of the compound of formula I further includes a preparation method of the compound of formula II, which includes the following step B: in a solvent, in the presence of an iodine reagent, 2-bromoethanol, the compound of formula III and the compound of formula IV react to obtain the compound of formula II, Preferably, the method for preparing the compound represented by formula II satisfies one or more of the following conditions: (1) The reaction temperature in step B is -5°C to 3°C, for example 0°C; (2) The solvent in step B is a halogenated hydrocarbon solvent and / or a heteroaromatic ring reagent, preferably a halogenated hydrocarbon solvent and a heteroaromatic ring reagent, such as dichloromethane and pyridine; (3) The iodine reagent is elemental iodine; (4) The molar ratio of the compound represented by formula III to the compound represented by formula IV is 1:1.6; and (5) the molar ratio of the compound represented by formula III to the 2-bromoethanol is 1:1.

6.

10. A compound as shown in formula II, in, R1, R2, m and n are as described in any one of claims 1 to 4; Preferably, the compound represented by formula II is the following compound, 11. A lipid nanoparticle, characterized in that: The lipid nanoparticles contain substance A, and the substance A is a phosphate compound shown in formula I as described in any one of claims 1 to 4 or a phosphate compound shown in formula Ia as described in any one of claims 5 to 7.

12. The lipid nanoparticle according to claim 11, characterized in that The lipid nanoparticles meet one or more of the following conditions: (1) The lipid nanoparticles further include a diluent; (2) The lipid nanoparticles further include phospholipids; (3) The lipid nanoparticles further include sterol; and (4) the lipid nanoparticles further comprise PEG lipids.

13. The lipid nanoparticle according to claim 12, characterized in that The lipid nanoparticles meet one or more of the following conditions: (1) The diluent is a pH buffer, such as a pH 4 buffer; (2) The phospholipid is DSPC, DMPC, DOPC, DPPC, DUPC or POPC, such as DSPC; (3) the sterol is selected from one or more of cholesterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, ursolic acid and α-tocopherol, such as cholesterol; (4) the PEG lipid is selected from one or more of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol and PEG-modified dialkylglycerol, such as PEG2000-C-DMG; (5) The molar ratio of the substance A to the phospholipid is 50:8.0 to 50:12.0, for example 50:10.0; (6) The molar ratio of the substance A to the sterol is 50:37.0 to 50:39.0, for example 50:38.5; and (7) the molar ratio of the substance A to the PEG lipid is 50:1.0 to 50:2.0, for example 50:1.4; Preferably, the lipid nanoparticles are composed of the substance A, the diluent, the phospholipid, the PEG lipid and the sterol; And / or, the lipid nanoparticle further comprises a therapeutic agent and / or a preventive agent, wherein the therapeutic agent and / or the preventive agent is preferably one or two or more nucleic acids, more preferably mRNA or siRNA, such as siRNA.

14. The lipid nanoparticle according to any one of claims 11 to 13, characterized in that The lipid nanoparticles meet one or more of the following conditions: (1) The average particle size of the lipid nanoparticles is preferably 80 to 100 nm; (2) The pKa of the lipid nanoparticles is preferably 6.2 to 6.8; (3) The cell viability of the lipid nanoparticles is preferably 96% to 98%; and (4) the lipid nanoparticles are prepared using microfluidic mixing technology.

15. A pharmaceutical composition comprising the lipid nanoparticle according to any one of claims 11 to 14 and a pharmaceutically acceptable carrier.

16. Use of a substance A as a formulation excipient, wherein the substance A is a phosphate compound represented by formula I as described in any one of claims 1 to 4 or a phosphate compound represented by formula Ia as described in any one of claims 5 to 7; preferably, the formulation excipient is a cationic lipid.

Citation Information

Patent Citations

  • Nanoparticle compositions

    CN112218533A

  • Lipid compounds and lipid nanoparticle compositions

    CN114206463A

  • Novel lipid nanoparticle for delivering nucleic acid medicine and preparation method of novel lipid nanoparticle

    CN115708809A

  • Lipid compound and the composition thereof

    WO2022112855A1